Cell: Fine-tuning of gene expression through the Mettl3-Mettl14-Dnmt1 axis controls ESC differentiation (Gupta Lab)

January 17, 2025

Giuseppe Quarto1,12 ∙ Andrea Li Greci1,12 ∙ Martin Bizet1,12 ∙ Audrey Penning1 ∙ Irina Primac1 ∙ Frédéric Murisier1 ∙ Liliana Garcia-Martinez2 ∙ Rodrigo L. Borges2 ∙ Qingzeng Gao3,4 ∙ Pradeep K.R. Cingaram2 ∙ Emilie Calonne1 ∙ Bouchra Hassabi1 ∙ Céline Hubert1 ∙ Adèle Herpoel1 ∙ Pascale Putmans1 ∙ Frédérique Mies1 ∙ Jérôme Martin1 ∙ Louis [...]

International Journal of Molecular Sciences: Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination Therapy (Penalva)

January 16, 2025

Jennifer Chiou Valeria Impedovo Yen Bao Huynh ,Ruggiero Gorgoglione Luiz O. F. Penalva Alessia Lodi Andrew J. Brenner Stefano Tiziani Abstract Glioblastoma (GBM), the most prevalent primary malignant brain tumor, remains challenging to treat due to extensive inter- and intra-tumor heterogeneity. This variability demands combination treatments to improve therapeutic outcomes. A significant obstacle in treating [...]

Aging Cell: Age-Dependent Bi-Phasic Dynamics of Ly49+CD8+ Regulatory T Cell Population (Rao)

December 19, 2024

Saranya Srinivasan, Shruti Mishra, Kenneth Ka-Ho Fan, Liwen Wang, John Im, Courtney Segura, Neelam Mukherjee, Gang Huang, Manjeet Rao, Chaoyu Ma, Nu Zhang ABSTRACT Aging is tightly associated with reduced immune protection but increased risk of autoimmunity and inflammatory conditions. Regulatory T cells are one of the key cells to maintaining immune homeostasis. The age-dependent changes in CD4+Foxp3+ regulatory T cells (Tregs) have been well […]


Clinical Cancer Research: Update on Surveillance for Wilms Tumor and Hepatoblastoma in Beckwith–Wiedemann Syndrome and Other Predisposition Syndromes (Tomlinson)

December 2, 2024

Update on Surveillance for Wilms Tumor and Hepatoblastoma in Beckwith–Wiedemann Syndrome and Other Predisposition Syndromes Jennifer M. Kalish Kerri D. Becktell Gaëlle Bougeard Garrett M. Brodeur Lisa R. Diller Andrea S. Doria Jordan R. Hansford Steven D. Klein Wendy K. Kohlmann Christian P. Kratz Suzanne P. MacFarland Kristian W. Pajtler Surya P. Rednam Jaclyn Schienda [...]

SLAS Discovery: The History, Landscape, and Outlook of Human Cell Line Authentication and Security (Pertsemlidis)

November 20, 2024

Elijah Harbut1,2,3 ∙ Yiorgos Makris4 ∙ Alexander Pertsemlidis5,6,7 ∙ Leonidas Bleris1,2,3 1 Introduction The phenomenon of cellular cross-contamination and misidentification (“CCCM”) was identified more than six decades ago and continues to pose significant challenges for laboratories globally. The prevalence of CCCM is alarmingly high, with estimates suggesting that up to 30% of cell lines may be misidentified, leading to substantial financial losses[2–4]. Accelerating progress in [...]

Molecular Cancer Therapeutics: Abstract B016: RNA demethylase ALKBH5 drives medulloblastoma growth and progression (Rao, Chen, Gupta, & Houghton Labs)

November 18, 2024

Panneerdoss Subbarayalu; Daisy Medina; Pitta Prabhakar; Shahad Abdulsahib; Saif Nirzhor; Desiree Denman; Santosh Timilsina; Deepika Singh; Phat Do; Krishna Evani; Dhiya Billa; Esha Reddy; Peter Houghton; Yogesh Gupta; Yidong Chen; Suryavathi Viswanadhapalli; Ratna Vadlamudi; Andrew Brenner; Manjeet Rao Abstract Introduction: Medulloblastoma (MB) is the most common malignant childhood brain tumor. It accounts for 20% of [...]

Pharmacology & Therapeutics: Lessons learned from 20 years of preclinical testing in pediatric cancers (Houghton, Kurmasheva)

November 11, 2024

Malcolm A. Smith a, Peter J. Houghton b, Richard B. Lock c, John M. Maris d, Richard Gorlick e, Raushan T. Kurmasheva b, Xiao-Nan Li f, Beverly A. Teicher a, Jeffrey H. Chuang g, Filemon S. Dela Cruz h, Michael A. Dyer i, Andrew L. Kung h, Michael W. Lloyd j, Yael P. Mosse d, Timothy M. Stearns j, Elizabeth A. Stewart i, Carol J. Bult j, Stephen W. Erickson k   Abstract Programs for preclinical testing of targeted cancer agents in murine models of childhood cancers have been supported by the National Cancer Institute (NCI) since 2004. These programs were established to work collaboratively with industry partners [...]

Molecular Oncology: Hijacking the BAF complex: the mechanistic interplay of ARID1A and EWS::FLI1 in Ewing sarcoma (Libich Lab)

October 3, 2024

Erich J. Sohn, David S. Libich Abstract Ewing sarcoma, an aggressive pediatric cancer, is driven by the EWS::FLI1 fusion protein, which disrupts gene expression by hijacking the BAF chromatin remodeling complex. Central to this mechanism is the formation of biomolecular condensates, mediated by the prion-like domains (PrLDs) of EWS and ARID1A, a core BAF subunit. ARID1A serves [...]

Vaccines: Pediatric Oncology Providers’ HPV Vaccine Knowledge, Attitude, Self-Efficacy, and Practice after Communication Training: A Comparison with a National Survey (Grimes)

October 3, 2024

Rejane A. Teixeira ,Allison Grimes,Leanne Embry,Christine Aguilar, L. Aubree Shay Abstract Background/Objectives: Human papillomavirus (HPV) vaccinations prevent HPV infection and related cancers. Despite being at higher risk of secondary cancers linked to HPV, childhood cancer survivors (CCS) are under-vaccinated. This study aimed to compare pediatric oncology providers’ knowledge, attitudes, self-efficacy, and practices regarding HPV vaccination [...]